Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas.

Related Articles

Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas.

Cancer Chemother Pharmacol. 2016 Nov;78(5):895-919

Authors: Nathenson MJ, Sausville E

Abstract
PURPOSE: Sarcomas are a rare and heterogeneous variant of cancer. The standard of care treatment involves surgical resection with radiation in high-risk patients. Despite appropriate treatment approximately 50 % of patients will suffer and die from recurrent disease. The purpose of this article is to review the current evidence concerning the use of neoadjuvant chemotherapy with or without radiation in soft tissue sarcomas.
METHODS: An in-depth literature search was conducted using Ovid Medline and PubMed.
RESULTS: The most active chemotherapeutic agents in sarcoma are anthracyclines and ifosfamide. Adjuvant chemotherapy trials show only minimal benefit. Neoadjuvant chemotherapy offers the potential advantage of reducing the extent of surgery, increasing the limb salvage rate, early exposure of micrometastatic disease to chemotherapy, and assessment of tumor response to chemotherapy. Some retrospective and phase II trials suggest a benefit to neoadjuvant chemotherapy. Unfortunately, no clearly positive phase III prospectively randomized trials exist for neoadjuvant therapy in soft tissue sarcomas.
CONCLUSIONS: The current neoadjuvant chemotherapy trials that do exist are heterogeneous resulting in conflicting results. However, neoadjuvant chemotherapy with or without radiation can be considered in patients with high-risk disease in an attempt to improve long-term outcomes.

PMID: 27206640 [PubMed - indexed for MEDLINE]

http://ift.tt/2rrSZhw